EGFR and non-small cell lung carcinoma: Osimertinib was first granted approval by FDA in 2015 [14], two years after receiving accelerated approval, for treatment of patients with metastatic EGFR T790M-positive NSCLC who have progressed on or after EGFR TKI [14].